<DOC>
	<DOC>NCT00553787</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of VI0521 compared to placebo in treatment of obesity in an adult population with obesity related co-morbid conditions.</brief_summary>
	<brief_title>Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Obesity</mesh_term>
	<criteria>Informed Consent BMI ≥ 27 (no lower BMI limit for Type 2 diabetics) 70 years of age or less Have 2 or more of the following obesityrelated comorbid conditions: Systolic blood pressure 140160 mmHg (130160 if diabetic); Diastolic blood pressure 90100 mmHg (85100 if diabetic); Requirement for 2 or more medications to achieve control (&lt;140/90 mmHg) Triglyceride level between 200400 mg/dL or requirement for 2 or more medications to achieve control (&lt;200 mg/dL) At lease one of the following metabolic criteria: Fasting blood glucose level &gt; 100 mg/dL Glucose level &gt; 140 mg/dL Diagnosis of type 2 diabetes Waist circumference ≥ 102 cm for men or ≥88 cm for women Stroke/MI/unstable cardiovascular disease within 6 months Clinically significant renal, hepatic or psychiatric disease Unstable thyroid disease or replacement therapy Nephrolithiasis Obesity of known genetic or endocrine origin Participation in a formal weight loss program or lifestyle intervention Glaucoma or intraocular pressure Pregnancy or breastfeeding Drug or Alcohol abuse Smoking cessation within previous 3 months or plans to quit smoking during study Eating disorders Cholelithiasis within past 6 months Excluded medications Type 1 diabetes or use of any antidiabetic medication other than metformin Previous bariatric surgery Bipolar disorder or psychosis Steroid hormone therapy Systolic blood pressure &gt; 160 mmHg, diastolic blood pressure &gt; 100 mmHg Creatinine clearance &lt; 60 mL/minute</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Obesity, Type 2 diabetes</keyword>
</DOC>